Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma
JNCI: Journal of the National Cancer Institute · 2023
DOI: 10.1093/jnci/djad062 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2023. Verfasst von Sara Viragova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Adenoid Cystic, Receptors, Retinoic Acid. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Adenoid cystic carcinoma (ACC) is a lethal malignancy of exocrine glands, characterized by the coexistence within tumor tissues of 2 distinct populations of cancer cells, phenotypically similar to the myoepithelial and ductal lineages of normal salivary epithelia. The developmental relationship linking these 2 cell types, and their differential vulnerability to antitumor treatments, remains unknown.
Methods
Using single-cell RNA sequencing, we identified cell-surface markers (CD49f, KIT) that enabled the differential purification of myoepithelial-like (CD49fhigh/KITneg) and ductal-like (CD49flow/KIT+) cells from patient-derived xenografts (PDXs) of human ACCs. Using prospective xenotransplantation experiments, we compared the tumor-initiating capacity of the 2 cell types and tested whether one could differentiate into the other. Finally, we searched for signaling pathways with differential activation between the 2 cell types and tested their role as lineage-specific therapeutic targets.
Results
Myoepithelial-like cells displayed higher tumorigenicity than ductal-like cells and acted as their progenitors. Myoepithelial-like and ductal-like cells displayed differential expression of genes encoding for suppressors and activators of retinoic acid signaling, respectively. Agonists of retinoic acid receptor (RAR) or retinoid X receptor (RXR) signaling (all-trans retinoic acid, bexarotene) promoted myoepithelial-to-ductal differentiation, whereas suppression of RAR/RXR signaling with a dominant-negative RAR construct abrogated it. Inverse agonists of RAR/RXR signaling (BMS493, AGN193109) displayed selective toxicity against ductal-like cells and in vivo antitumor activity against PDX models of human ACC.
Conclusions
In human ACCs, myoepithelial-like cells act as progenitors of ductal-like cells, and myoepithelial-to-ductal differentiation is promoted by RAR/RXR signaling. Suppression of RAR/RXR signaling is lethal to ductal-like cells and represents a new therapeutic approach against human ACCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA.
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
- Columbia Stem Cell Initiative, Columbia University Medical Center, New York, NY, USA.
- Integrated Program in Cellular, Molecular and Biomedical Studies, Columbia University, New York, NY, USA.
- Program for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA.
- Department of Biomedical Informatics, Columbia University, New York, NY, USA.
ORCID-Profile: Sara Viragova, Luis Aparicio, Pierangela Palmerini, Junfei Zhao, Luis E Valencia Salazar, Alexandra Schurer, Debashis Sahoo, Christopher A Moskaluk, Raul Rabadan, Piero Dalerba
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NCATS NIH HHS
- NIDCR NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- Adenoid Cystic Carcinoma Research Foundation
- Damon Runyon Cancer Research Foundation
Zitieren
APA
Viragova, S., Aparicio, L., Palmerini, P., Zhao, J., Valencia Salazar, L. E., Schurer, A., Dhuri, A., Sahoo, D., Moskaluk, C. A., Rabadan, R., & Dalerba, P. (2023). Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad062
Vancouver
Viragova S, Aparicio L, Palmerini P, Zhao J, Valencia Salazar LE, Schurer A, et al. Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma. JNCI: Journal of the National Cancer Institute. 2023. doi:10.1093/jnci/djad062
BibTeX
@article{Viragova2023,
author = {Viragova, Sara and Aparicio, Luis and Palmerini, Pierangela and Zhao, Junfei and Valencia Salazar, Luis E and Schurer, Alexandra and Dhuri, Anika and Sahoo, Debashis and Moskaluk, Christopher A and Rabadan, Raul and Dalerba, Piero},
title = {Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2023},
doi = {10.1093/jnci/djad062}
}
EUVIMED